Revolutionizing medicine with toll-like receptors: A path to strengthening cellular immunity.


Journal

International journal of biological macromolecules
ISSN: 1879-0003
Titre abrégé: Int J Biol Macromol
Pays: Netherlands
ID NLM: 7909578

Informations de publication

Date de publication:
31 Dec 2023
Historique:
received: 03 06 2023
revised: 01 10 2023
accepted: 03 10 2023
medline: 27 11 2023
pubmed: 7 10 2023
entrez: 6 10 2023
Statut: ppublish

Résumé

Toll-like receptors play a vital role in cell-mediated immunity, which is crucial for the immune system's defense against pathogens and maintenance of homeostasis. The interaction between toll-like-receptor response and cell-mediated immunity is complex and essential for effectively eliminating pathogens and maintaining immune surveillance. In addition to pathogen recognition, toll-like receptors serve as adjuvants in vaccines, as molecular sensors, and recognize specific patterns associated with pathogens and danger signals. Incorporating toll-like receptor ligands into vaccines can enhance the immune response to antigens, making them potent adjuvants. Furthermore, they bridge the innate and adaptive immune systems and improve antigen-presenting cells' capacity to process and present antigens to T cells. The intricate signaling pathways and cross-talk between toll-like-receptor and T cell receptor (TCR) signaling emphasize their pivotal role in orchestrating effective immune responses against pathogens, thus facilitating the development of innovative vaccine strategies. This article provides an overview of the current understanding of toll-like receptor response and explores their potential clinical applications. By unraveling the complex mechanisms of toll-like-receptor signaling, we can gain novel insights into immune responses and potentially develop innovative therapeutic approaches. Ongoing investigations into the toll-like-receptor response hold promise in the future in enhancing our ability to combat infections, design effective vaccines, and improve clinical outcomes.

Identifiants

pubmed: 37802429
pii: S0141-8130(23)04149-1
doi: 10.1016/j.ijbiomac.2023.127252
pii:
doi:

Substances chimiques

Toll-Like Receptors 0
Vaccines 0
Adjuvants, Immunologic 0
Antigens 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

127252

Informations de copyright

Copyright © 2023 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare no conflict of interest.

Auteurs

Jonaid Ahmad Malik (JA)

Immunology Laboratory, Department of Biomedical Engineering, Indian Institute of Technology, Ropar, Punjab 140001, India.

Gurpreet Kaur (G)

Immunology Laboratory, Department of Biomedical Engineering, Indian Institute of Technology, Ropar, Punjab 140001, India; Department of Biotechnology, Chandigarh Group of Colleges, Landran, Mohali, Punjab 140055, India.

Javed N Agrewala (JN)

Immunology Laboratory, Department of Biomedical Engineering, Indian Institute of Technology, Ropar, Punjab 140001, India. Electronic address: jagrewala@gmail.com.

Articles similaires

The FGF/FGFR/c-Myc axis as a promising therapeutic target in multiple myeloma.

Arianna Giacomini, Sara Taranto, Giorgia Gazzaroli et al.
1.00
Humans Multiple Myeloma Receptors, Fibroblast Growth Factor Fibroblast Growth Factors Proto-Oncogene Proteins c-myc
Animals Lung India Sheep Transcriptome

Calcineurin inhibition enhances

Priyanka Das, Alejandro Aballay, Jogender Singh
1.00
Animals Caenorhabditis elegans Longevity Caenorhabditis elegans Proteins Calcineurin
1.00
Animals Mice Immunity, Innate Interneurons Synapses

Classifications MeSH